Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1

Status

Unknown 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 14Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Esophageal Neoplasms 12Cholangiocarcinoma 10Lung Neoplasms 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Small Cell Lung Carcinoma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Nasopharyngeal Carcinoma 6Melanoma 5Colonic Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Locally Advanced Rectal Cancer 4Hodgkin Disease 4Neoplasms 3NSCLC 3Lymphoma, Extranodal NK-T-Cell 3Glioblastoma 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2

Interventions

Cyclophosphamide 115fludarabine phosphate 67Mycophenolic Acid 62Etoposide 61Peripheral Blood Stem Cell Transplantation 58Tacrolimus 55Melphalan 48Filgrastim 48Busulfan 48Whole-Body Irradiation 47Doxorubicin 46Radiotherapy 42fludarabine 38Cyclosporine 38Brentuximab Vedotin 38Vinblastine 35Granulocyte Colony-Stimulating Factor 35Antilymphocyte Serum 30Methotrexate 29Dacarbazine 29Gemcitabine 28Rituximab 26Nivolumab 25Prednisone 24Bleomycin 24Vincristine 22pembrolizumab 21Carmustine 21Cytarabine 20thymoglobulin 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Hodgkin Disease × tislelizumab × Clear all
NCT05502250 2026-03-06

HOVON164HL

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Hodgkin Disease

NCT05977673 2025-12-08

FIL_Tisle-HL

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting
28 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

NCT05627115 2023-11-29

RATiFY

University College, London

Phase 2 Not yet recruiting
80 enrolled
Lymphoid

Hodgkin Disease

NCT04843267 2021-04-13

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Sun Yat-sen University

Phase 2 Unknown
30 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡